# US 2023/0404934 A1 · On demand and long-term drug delivery from degradable nanocapsules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0404934 A1
- Document ID: US20230404934A1
- Status: Published application
- Kind: A1
- Application number: 18/299,135
- Filed: 2023-04-12
- Published: 2023-12-21
- Earliest claimed: 2020-10-14
- Assignees: University of Maryland, Baltimore County
- Applicants: University of Maryland, Baltimore County
- Inventors: Erin LAVIK; Sydney MENIKHEIM; Joshua LECKRON
- Web page: https://patentgrep.com/patent/US20230404934A1

## CPC

- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/5192: {Processes}
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 41/0047: {Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent}
- A61P 27/02: Ophthalmic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A long-term delivery system for age-related macular degeneration (AMD) that can address the multifactorial nature of the disease. A polyurethane nanocapsule is disclosed that includes encapsulated molecules that treat AMD. The molecules can be passively delivered from the polyurethane nanocapsules over many weeks or months and/or can be tuned, non-invasively, using ultrasound to trigger the release the molecules from the polyurethane nanocapsules repeatedly in an on-demand and predictable manner. These nanocapsules have the potential to change the way diseases are treated and provide a new ultrasound-triggered drug delivery platform.

## Claims

### Claim 1

Polyurethane nanocapsules comprising a substantially spherical shell of polyurethane surrounding a core, wherein the shell comprising the polyurethane further comprises at least one molecule to be encapsulated.

### Claim 2 (depends on 1)

The polyurethane nanocapsules of claim 1, wherein the at least one molecule is homogeneously or heterogeneously distributed throughout the substantially spherical shell of polyurethane.

### Claim 3 (depends on 1)

The polyurethane nanocapsules of claim 1, wherein the at least one molecule is exposed on an outside surface of the shell, exposed on an inside surface of the shell, and/o encapsulated within the shell between the outside surface and the inside surface.

### Claim 4 (depends on 1)

The polyurethane nanocapsules of claim 1, wherein the core comprises at least one of air, a hydrophilic liquid, a hydrophobic liquid, or a contrast agent.

### Claim 5 (depends on 1)

The polyurethane nanocapsules of claim 1, wherein the molecule to be encapsulated comprises a species selected from the group consisting of acriflavine, pirfenidone, 4-hydroxy-TEMPO, growth factors, AG1478, methotrexate, and antibiotic agents.

### Claim 6 (depends on 1)

The polyurethane nanocapsules of claim 1, having an effective mean diameter of about 50 to about 900 nm.

### Claim 7 (depends on 1)

The polyurethane nanocapsules of claim 1, wherein the nanocapsules can be lyophilized and resuspended.

### Claim 8 (depends on 1)

The polyurethane nanocapsules of claim 1, wherein the polyurethane nanocapsule undergoes long-term passive delivery of the molecule into an environment in proximity of the nanocapsule.

### Claim 9 (depends on 1)

The polyurethane nanocapsules of claim 1, wherein the polyurethane nanocapsule can be triggered using ultrasound to release the molecule, on-demand, into the environment in proximity of the nanocapsule.

### Claim 10 (depends on 1)

A method of making the polyurethane nanocapsules of claim 1, said method comprising:
dissolving surfactant in water and hexadecane to form a mixture;
stirring or sonicating the mixture at temperature in a range from about 35-45° C.;
adding isophorone diisocyanate (IPDI) to the stirred mixture comprising the water, surfactant, and hexadecane to form a solution;
sonicating the solution to form an emulsion;
adding a hydroxy-containing compound to the emulsion, with continued sonication; and
reacting the IPDI and the hydroxy-containing compound, with stirring, to form the polyurethane nanocapsules encapsulating the at least one molecule,
wherein the molecule to be encapsulated is added with the IPDI or the hydroxy-containing compound, depending on the solubility of the molecule to be encapsulated.

### Claim 11 (depends on 1)

A method of inhibiting neovascularization in an eye of a subject in need thereof, said method comprising administering a long-term delivery system comprising the polyurethane nanocapsules of claim 1 to the eye of said subject, wherein the at least one molecule to be encapsulated comprises acriflavine.

### Claim 12 (depends on 11)

The method of claim 11, wherein the polyurethane nanocapsules can passively deliver the acriflavine and/or they can be repeatedly triggered to release highly controlled and reproducible amounts of acriflavine in response to an amount of ultrasound energy applied to the nanocapsules.

### Claim 13 (depends on 1)

A method of substantially reducing or eliminating fibrosis in an eye of a subject in need thereof, said method comprising administering a long-term delivery system comprising the polyurethane nanocapsules of claim 1 to the eye of said subject, wherein the at least one molecule to be encapsulated comprises pirfenidone.

### Claim 14 (depends on 13)

The method of claim 13, wherein the polyurethane nanocapsules can passively deliver the pirfenidone and/or they can be repeatedly triggered to release highly controlled and reproducible amounts of pirfenidone in response to an amount of ultrasound energy applied to the nanocapsules.

### Claim 15 (depends on 1)

A method of inhibiting neovascularization and substantially reducing or eliminating fibrosis in an eye of a subject in need thereof, said method comprising administering a combination therapy or dual delivery system comprising the polyurethane nanocapsules of claim 1 to the eye of said subject, wherein some portion of the polyurethane nanocapsules comprise encapsulated acriflavine and the remaining portion of the polyurethane nanocapsules comprise encapsulated pirfenidone.

### Claim 16 (depends on 15)

The method of claim 15, wherein the polyurethane nanocapsules can passively deliver the pirfenidone and acriflavine and/or they can be repeatedly triggered to release highly controlled and reproducible amounts of pirfenidone and acriflavine in response to an amount of ultrasound energy applied to the nanocapsules.

### Claim 17 (depends on 1)

A method of treating wet-AMD, or preserving vision, in an eye of a subject in need thereof, said method comprising administering a long-term delivery system comprising the polyurethane nanocapsules of claim 1 to the eye of said subject, wherein the at least one molecule to be encapsulated is selected from acriflavine, pirfenidone, or both acriflavine and pirfenidone.

### Claim 18 (depends on 17)

The method of claim 17, wherein the polyurethane nanocapsules can passively deliver the pirfenidone and acriflavine and/or they can be repeatedly triggered to release highly controlled and reproducible amounts of pirfenidone and acriflavine in response to an amount of ultrasound energy applied to the nanocapsules.

### Claim 19 (depends on 11)

The method of claim 11, wherein the polyurethane nanocapsules can be administered intravitreally, suprachoroidally, or subcunjunctivally.
